Well Referenced

Tag: Tau Pathology

Insights into the Potential Role of Mercury in Alzheimer’s Disease

This review examines the neurotoxic potential of mercury (Hg) in the pathogenesis of Alzheimer’s disease (AD). Mercury exposure—from environmental sources like atmospheric emissions and dietary intake of methylmercury—is proposed to disrupt multiple neurotransmitter systems, including serotonin, dopamine, acetylcholine, and glutamate. Additionally, mercury interferes with critical biochemical pathways involving homocysteine, arachidonic

Read More »
June 26, 2025 No Comments

Cotinine: a potential new therapeutic agent against Alzheimer’s disease

This review investigates cotinine, a non-toxic metabolite of nicotine, as a potential treatment for Alzheimer’s disease (AD). Preclinical studies have shown that cotinine enhances memory, reduces amyloid-beta (Aβ) pathology, and mitigates tau-related neurotoxicity in animal models. Mechanistically, cotinine appears to modulate α7 nicotinic acetylcholine receptors (α7nAChRs), activate the Akt signaling

Read More »
June 26, 2025 No Comments

Rapamycin and Alzheimer’s Disease: Time for a Clinical Trial?

This 2019 opinion article by Matt Kaeberlein and Veronica Galvan advocates for initiating clinical trials to assess rapamycin’s efficacy in treating Alzheimer’s disease (AD). Despite compelling preclinical evidence demonstrating rapamycin’s benefits in animal models—such as reducing amyloid-beta and tau pathology, improving cognitive function, and enhancing synaptic plasticity—no human trials had

Read More »
June 26, 2025 No Comments